Login

Join for Free!
18543 members
Home Forum Dictionary Articles Tutorials Books Directory Share your work
table of contents table of contents

Biology Articles » Biochemistry » Enzymology » Cytochrome P450 enzyme isoforms and their therapeutic implications: An update » References

References
- Cytochrome P450 enzyme isoforms and their therapeutic implications: An update

1. Rang HP, Dale MM, Fitter JM, Moore PK, editors. Pharmacology. 5th ed. Churchill Livingstone: Edinburg; 2003.    
2. Pirmohamed M, Park BK. Cytochrome P450 enzyme polymorphism and adverse drug reactions. Toxicology 2003;192:23-32.  
3. Wrighton SA, Stevens JC. The human hepatic cytochromeP450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21. 
4. Coon MJ. Cytochrome P450: Nature's most versatile biological catalyst. Ann Rev Pharmacol Toxicol 2005;45:1-25. 
5. Cupp MJ, Tracy TS. Cytochrome P450: New nomenclature and clinical implications. Am Fam Phys 1998;57:107-16.  
6. Wheeler CW, Guenthner TM. Spectroscopic quantitation of cytochrome P450 in human lung microsomes. J Biochem Toxicol 1990;5:269-72.  
7. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, et al . P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996;6:1-42. 
8. Chang GW, Kam PC. The physiological and pharmacological role of CYP450 isoenzymes. Anesthesia 1999;54:42-50.
9. Yan Z, Caldwell GW. Metabolism profiling and cytochrome P450 inhibition and induction in drug discovery. Curr Topics Med Chem 2001;1:403-25.   
10. Ingelman Sundberg M. Pharmacogenetics of cytochrome P450 and its application in drug therapy: The past, present and the future. Trends Pharmacol Sci 2004;25:193-200. 
11. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450: An opportunity for individual drug treatment. Trends Pharmacol Sci 1999;20:342-9.   
12. McGinnity DF, Riley RJ. Predicting drug pharmacokinetics in humans from in vitro metabolism studies. Biochem Soc Trans 2001;29:135-9.  
13. de Leon J. AmpliChip CYP450 Test: Personalized medicine has arrived in psychiatry. Expert Rev Mol Diagn 2006;6:277-86.
14. Ingelman-Sundberg M. Pharmacogenetics: An opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001;250:186-200. 
15. Ioannides C, editor. Cytochromes P450 Metabolic and Toxicological Aspects. CRC Press Inc: New York; 1996.  
16. Xie W, Barwick JL, Simon CM, Pierce AM, Safe S, Blumberg B, et al . Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev 2000;14:3014-23.     
17. Wei P, Zhang J, Egan-Hafley M, Liang S, Moore DD. The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature 2000;407:920-3.  
18. Honkakoski P, Negishi M. Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J 2000;347:321-37. 
19. Tanaka E, Hisawa S. Clinically significant pharmacokinetic drug interactions with psychoactive drugs: Antidepressants and antipsychotics and the cytochrome P450 system. J Clin Pharm Ther 1999;24:7-16.
20. Pelkonen O, Pasanen M, Kuha H, Gachalyi B, Kairaluoma M, Sotaniemi EA, et al . The effect of cigarette smoking on 7-ethoxyresorufin O-deethylase and other monooxygenase activities in human liver: Analyses with monoclonal antibodies. Br J Clin Pharmacol 1986;22:125-34. 
21. Kinirons MT, Crome P. Clinical pharmacokinetic considerations in the elderly: An update. Clin Pharmacokinet 1997;33:302-12.
22. Ereshefsky L, Riesenman C, Lam YW. Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. J Clin Psychiatry 1996;57:17-25.  
23. Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, Sugiyama Y. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharma Res 2000;17:419-26. 
24. Cummins LH, Kozek PP Jr, Gillman SA. Erythromycin's effect on theophylline blood level. Pediatrics 1977;59:144.  
25. Honig PK, Worthom DC, Zamani K, Cantilena LR. Comparison of the effect of erythromycin, clarithromycin and azithromycin on terfenadine steady state pharmacokinetics and ECG parameters. Drug Invest 1994;7:148-56.  
26. Kenworthy KE, Bloomer JC, Clarke SE, Houston JB. CYP3A4 drug interactions: Correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 1999;48:716-27.
27. Sarkar M, Polk RE, Guzelian PS, Hunt C, Karnes HT. In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes. Antimicrob Agents Chemother 1990;34:594-9. 
28. Hamman MA, Thompson GA, Hall SD. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol 1997;54:33-41.
29. Knodell RG, Hall SD, Wilkinson GR, Guengerich FP. Hepatic metabolism of tolbutamide: Characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J Pharmacol Exp Ther 1987;241:1112-9. 
30. Miners JO, Rees DL, Valente L, Veronese ME, Birkett DJ. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. J Pharmacol Exp Ther 1995;272:1076-81. 
31. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, et al . Hydroxylation of warfarin by human c DNA expressed cytochrome P450: A role for P 4502C9 in the etiology of S-warfarin drug interactions. Chem Res Toxicol 1992;5:54-9. 
32. Heimark LD, Wienkers L, Kunze K, Gibaldi M, Eddy AC, Trager WF, et al . the mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther 1992;51:398-407.  
33. Yue QY, Svensson JO, Alm C, Sjoqvist F, Sawe J. Codeine O-demethylation co segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol 1989;28:639-45.
34. Greenbalt DJ, von Moltkell LL, Harmatz JS, Shader RI. Drug interactions with newer antidepressants: Role of human cytochrome P450. J Clin Psychiatry 1998;59:19-27. 
35. Lane R, Baldwin D. Selective serotonin uptake inhibitor induced serotonin syndrome. J Clin Psychopharmacol 1997;17:208-21. 
36. Kharasch ED, Armstrong AS, Gunn K, Artru A, Cox K, Karol MD. Clinical sevoflurane metabolism and disposition. II. The role of cytochrome P450 2E1 in fluoride and hexafluoroisopropanol formation. Anesthesiology 1995;82:1379-88. 
37. Whitcomb DC, Block GD. Association of acetaminophen toxicity with fasting and ethanol use. JAMA 1994;272:1845-50. 
38. Klotz U, Ammon E. Clinical and toxicological consequences of the inductive potential of ethanol. Eur J Clin Pharmacol 1998;54:7-12.
39. Knodell RG, Browne DG, Gwozdz GP, Brian WR, Guengerich FP. Differential inhibition of individual human liver cytochrome P450 by cimetidine. Gastroenterology 1991;101:1680-91.
40. Waxman DJ. Steroid hormones and other physiological regulators of liver cytochrome P450: Metabolic reactions and regulatory pathways. Adv Mol Cell Biol 1996;14:341-74.  
41. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. 1998. Br J Clin Pharmacol 2004;58:S831-43.  
42. Garteiz DA, Hook RH, Walker BJ, Okerholm RA. Pharmacokinetics nd biotransformation studies of terfenadine in man. Arzneimittelforschung 1982;32:1185-90. 
43. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996;335:290-1. 
44. Centers for Disease Control and Prevention (CDC). Clinical update: Impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR Morb Mortal Wkly Rep 1996;45:921-5.
45. Tandon VR, Kapoor B, Bano G, Gupta S, Gillani Z, Gupta S, Kour D. P-glycoprotein: Pharmacological relevance. Indian J Pharmacol 2006;38:13-24. 
46. Kivisto KT, Niemi M, Fromm MF. Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol 2004;18:621-6.  

rating: 0.00 from 0 votes | updated on: 17 May 2007 | views: 1006 |

share this article | email to friends

suggest a revision
print this page
print the whole article

Rate article:







excellent!bad…